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Treatment-resistant hypertension (TRH), the persistent
elevation of systolic blood pressure >140 mm Hg despite
treatment with maximal or highest tolerated doses of at
least three antihypertensive medications, one of which is
a diuretic (1), remains a signiﬁcant clinical challenge and
a source of concern among patients, physicians, and public
health policy makers. TRH patients face increased rates
of cardiovascular-related morbid and mortal events that
represent a signiﬁcant burden on already constrained med-
ical resources. Current estimates suggest that 10% to 15% of
the patients referred for hypertension evaluation meet the
TRH deﬁnition (2) and, until recently, had few thera-
peutic options. The Symplicity HTN-1 (3) and -2 (4) trials
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established the facts that percutaneous catheter-based
radiofrequency renal sympathetic denervation (RDN) is a
safe and effective therapy in highly selected patients with
severe TRH (blood pressure:>160 mmHg or>150 mmHg
in patients with type 2 diabetes and appropriate renal
artery anatomy) and results in a signiﬁcant blood pressure
reduction through 30-month follow-up (5). However, the
safety and effectiveness of RDN has yet to be deﬁned in
a potentially larger cohort of patients who meet the clinical
deﬁnition of TRH (i.e., >140 mm Hg) but not the stricter
blood pressure inclusion criteria of >160 mm Hg of the
Symplicity trials.
In this issue of the Journal, Ott et al. (6) present a multi-
center, prospective, open label, nonrandomized registry of 54
patients with moderate TRH (ofﬁce blood pressure:140/90
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for Medtronic.pressure monitoring of 130/80 mm Hg). The authors
conclude, based on the results of baseline ﬁndings and of
6-month follow-up in 54 patients, that RDN using the
Symplicity catheter (Ardian Medtronic, Mountain View,
California) reduced ofﬁce blood pressure by a mean of 13/7
mm Hg (n ¼ 54) and 24-h ambulatory blood pressure by
a mean of 14/7 mmHg (n ¼ 34) from a baseline value of 151
 6 mm Hg while receiving a mean of 5.1 medications,
noting a positive 6-month “responder” rate (deﬁned as
a systolic blood pressure response of >10 mm Hg) of 61%
with 51% achieving an ofﬁce blood pressure of 140/90
mm Hg. This registry represents a pilot validation of RDN
in patients with moderate TRH, in distinction to the severe
TRH cohort evaluated in the Symplicity HTN-1 and -2 trials
and the U.S. pivotal Symplicity HTN-3 trial, which recently
completed enrollment. Importantly, this registry now sets the
stage for the recently announced Symplicity HTN-4 trial,
a randomized, controlled evaluation of RDN in this moderate
TRH cohort.
The Symplicity HTN-1 and -2 trial results suggest that
RDN in severe TRH patients lowers systolic blood pressure
27 mm Hg (1,2). This is the equivalent of the blood
pressure-lowering effect of 2 1/2 classes of antihypertensive
medications. However, as expected, the systolic blood
pressure-lowering effect in patients with moderate TRH was
lower, averaging approximately 13 mm Hg. Despite this, it
must be recognized that the blood pressure-lowering effect
of this degree has important potential socioeconomic
consequences, with expected reductions in cardiovascular
complications and the potential for reduced antihypertensive
medications costs. A state transition model suggests that
RDN in severe TRH patients is highly cost effective (7);
however, whether the same can be said for treatment of
moderate TRH awaits a larger, randomized controlled trial
and long-term follow-up.
There is a strong argument for reconsidering in this
moderate TRH cohort, and all future RDN trials, the use of
the “responder” versus the “non-responder” endpoint deﬁ-
nition, a pre-speciﬁed arbitrary systolic blood pressure
lowering of 10 mm Hg compared to baseline, used to
infer successful blood pressure response, and also used in
the Symplicity HTN-1 and -2 trials. A 6-month successful
“responder” rate of 90% was ﬁrst reported in Symplicity
HTN-1, which declined to 78.7% at 12 months in
the RDN treatment arm of Symplicity HTN-2 (4). The
terms are of little clinical utility, taking a continuous and
dynamic variable (systolic blood pressure response) and
converting it into a dichotomous, binary term. Furthermore,
the actual systolic blood pressure values of these “non-
responders” in the Symplicity HTN-1 and -2 trials have
never been reported, preventing any potential valuable
insights into the demographics of this patient cohort, leaving
readers to hypothesize whether “non-responders” had
a mean systolic blood pressure decline of 7 to 8 mm Hg,
which would be considered a favorable response in any
antihypertension drug trials, or whether it represented an
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Ott et al. (6) found that approximately 50% of patients
experienced a systolic blood pressure reduction, reaching
the “goal” of 140 mm Hg: a signiﬁcant benchmark
associated with a reduction in cardiovascular events (despite
the reduction in the number of antihypertensive medications
prescribed by referring physicians). This key therapeutic
endpoint was reached even with a 38.9% “non-responder”
rate; notably, the investigators observed a slight increase
of 7  13 mm Hg in systolic blood pressure at 6 months
in these “non-responders.” While this blood pressure
increase may represent a normal variation in blood pressure
values in a small patient cohort at 6 months and/or
patient medical noncompliance, the actual reporting of
the “non-responder” blood pressure values is essential in
future larger, randomized RDN trials; understanding
whether nonresponse actually means “no response” or “worst
response” post-RDN may assist in identifying patient-
related pre-procedure predictors of clinical blood pressure
response or the lack thereof.
In a pre-speciﬁed analysis of 10,705 patients in the
ACCOMPLISH (Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with Systolic
Hypertension) trial (8), which compared benazepril and
amlodipine to benazepril and hydrochlorothiazide, treating
patients with high-risk hypertension with the goal of
lowering systolic blood pressure below 140 mm Hg, but
no lower than 130 mm Hg, appeared to be the best thera-
peutic target. Every endpoint used to assess outcomes
improved signiﬁcantly if systolic blood pressure was brought
to 130 to 139 mm Hg compared with higher pressures.
Achieving a systolic pressure of 120 to 129 mm Hg was of
minimal additional beneﬁt to patients; however, a more
aggressive reduction to 110 to 119 mm Hg was harmful to
some patients. Reaching systolic blood pressures below
120 mm Hg reduced the risk of stroke but was associated
with two coronary events for every stroke prevented. If
these studies inﬂuence future guidelines, RDN as a thera-
peutic strategy in moderate TRH patients may likely
increase the number of patients that could reach the ideal
therapeutic goal.
As the RDN procedure evolves, the durability of its blood
pressure-lowering effect and safety suggests that this thera-
peutic strategy and its clinical indications will continue to
evolve and expand. Selection of patients with severe or
moderate TRH, thus far, has required that the patients be
receiving three or more antihypertensive medications at full
or tolerated doses, including a diuretic. These patients have
had maximal antihypertensive therapy directed at activity
of the renin-angiotensin system and sodium volume-
contributing factors. This has resulted in selection of
patients who most likely have increased sympathetic nervous
system activity as a contributing factor to their TRH. Future
studies should deﬁne whether aldosterone receptor blocker
agents should be initiated as part of the screening process, as
increased aldosterone can contribute to TRH. Alternatively,if there is uncertainty as to whether increased sympathetic
nervous system activity is contributing to a patient’s TRH,
prediction of which patients will respond to RDN may be
made more speciﬁc by testing the blood pressure response to
the administration of oral clonidine (0.1 mg every 12 h for 1
week). Clonidine, a central alpha agonist, reduces central
sympathetic outﬂow, thus interrupting the sensory afferent
renal nerve-central integration-increased peripheral sympa-
thetic nervous system activity reﬂex arc. Our experience
indicates that patients who responded to clonidine with
a decline of 10 mm Hg in systolic blood pressure subse-
quently responded to RDN with even greater arterial pres-
sure lowering. Thus, the positive predictive value of this
screening test appears high. The greater blood pressure
response to RDN than that to clonidine may reﬂect a limi-
tation of the ability of clonidine treatment to reduce central
sympathetic outﬂow without encountering its adverse drug
side effects.
An important topic, which has received little attention, is
the question of what post-RDN antihypertensive therapy
should be advised long-term. Because RDN results in
decreased central sympathetic outﬂow, therapy directed at
activity of the renin-angiotensin-aldosterone system and
sodium-volume factors would appear to be appropriate long-
term antihypertensive choices. While reduction of the
number of required antihypertensive medications in
some patients is possible, the long-term strategy should be
to attain antihypertensive goals that decrease long-term
cardiovascular risks. Future studies should help develop
long-termmedication strategies to assist physicians in making
thoughtful long-term adjustments in medications in RDN
patients.
The Symplicity HTN-1 and -2 trials and the present
registry used a 6-month primary time point at which to
assess blood pressure by comparison to pre-RDN control
values. However, longer-term follow-up in severe TRH
patients is essential to identify a group of “slow responders”
who do not manifest a blood pressure-lowering effect for
up to a year (4). Thus, the reported 6-month blood pres-
sure response by Ott et al. (6) may turn out to be more
beneﬁcial than reported and the maximal blood pressure
reduction in this moderate-THR cohort may yet be fully
realized.
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